Smart Labtech’s Director Koundinya Lays Down a 2050 Vision at ASM 2026
Become a Manufacturer—or Plateau Forever
Manufacturing Builds Profit, Technology Builds Valuation
₹1,000 Crore by Design: Smart Labtech’s 2050 Mandate
Stop Waiting- The Execution Window Begins (2050 Vision)
Distribution Is a Step. The Brand Is the Goal.
There is a particular moment in the life of any institution — family-built, founder-led, two-and-a-half decades old — when the next generation steps to the front of the room. Not to receive an introduction. Not to offer pleasantries. But to speak, with full authority, about where the organisation goes from here.
That moment arrived at ASM 2026 on the morning of 15th April, when Rama Koundinya Potharaju — Director of Smart Labtech Private Limited and son of the Managing Director Sri Venkata Satya Prasad Potharaju — delivered his presentation: Smart Vision Beyond 25 Years — 2050.
It was assertive. It was honest. It was, at moments, bluntly uncomfortable — the kind of discomfort that only comes when someone who knows the organisation from the inside chooses to say what needs to be said rather than what the room might prefer to hear. And woven through the data and the strategy and the scenario planning was a mission statement delivered not as a resolution but as a quiet ultimatum to the assembled team:
Become a manufacturer. Build a brand. Reach ₹1,000 crore — or remain what you are.
Beginning With Gratitude — Then Moving Quickly Past It
Koundinya opened by asking the room to applaud themselves — for surviving COVID, for sustaining through lockdowns, for emerging into a Silver Jubilee year as a ₹100 crore company. He meant it. But he spent precisely twenty seconds on it.
Because the point of the presentation was not celebration. It was navigation. “These are times when we can’t even plan what’s going to happen next moment,” he acknowledged, with a candour that cut through the motivational gloss that might have coloured a lesser presentation. “And 25 years vision planning is a bigger thing.”
Then he began.
Twenty-Five Years in Five Acts
Koundinya structured Smart Labtech’s history into five phases — not as nostalgia, but as a diagnostic. Each phase revealed a pattern of deliberate evolution:
2001–2005 — Foundation: A small-scale start-up, trader and distributor, focused on analytical instruments and weighing equipment. “We built a robust vendor network and customer base.” The people who were there from the very beginning — Ramana sir, Pawan, Satyajit — were identified by name from the dais.
2006–2012 — Expansion: International brands onboarded, beginning with Sartorius and Memmert. Pharmaceutical, biotech, and R&D laboratories became the core constituency. The company transitioned from trader to solution provider.
2013–2018 — Scaling and Diversification: The manufacturing chapter opened — platform scales, customised lab solutions, strengthened service and maintenance. A hybrid business model emerged: manufacturer, supplier, and service provider under one roof.
2019–2023 — Modernisation: Advanced lab technologies, life sciences and biotech equipment, genomics support tools. A steady 9–10% annual growth. Revenue growing, net worth increasing.
2023–2026 — Current Phase: 125 to 140 employees, pan-India distribution, ₹100 crore in revenue — and a company standing at what Koundinya clearly sees as the most consequential inflection point in its history.
The Diagnosis — Honest, Without Apology
Before presenting the vision, Koundinya presented the vulnerabilities. And he did not soften them.
Market saturation risk: “Earlier, in 2010 to 2015, you could name on your fingertips the companies dealing with analytical equipment. Right now, there is a company for every street.” The competitive landscape has transformed entirely, and Smart Labtech’s strategies have not yet caught up with that transformation.
Import dependency: “We are mostly dependent on imports and OEM partnerships. We are not a major manufacturing hub yet.” Our hands, he noted pointedly, are “tied according to their terms and conditions” — principal policies constrain market exploration in ways that a genuine manufacturer never faces.
Industry concentration: Pharma dominates the portfolio. Food, beverages, oil, rubber, plastics — these sectors remain largely unexplored, approached on an order-by-order basis rather than through active, structured market development.
Geographic limitation: “We don’t go beyond boundaries, which is a major factor for our company’s growth restriction.” Teams stay within their comfort territories. The tier-2 and tier-3 cities remain largely uncaptured.
Talent gap: Skilled engineers have options. Software companies offer comfort, salary, and stability. “Earlier, people in that era would really like to explore, go meet customers, make connections. Right now, people want to sit comfortably in AC in front of a computer.” The pipeline of field-ready technical talent is shrinking at precisely the moment Smart Labtech needs more of it.
He said all of this without accusation, without sentimentality, and without the careful hedging that characterises presentations designed to avoid discomfort. For someone presenting in front of an assembled team that includes senior employees who have been with the company for fifteen years, this was a choice — and it was the right one.
Three Scenarios — And a Clear Preference
Koundinya presented three growth scenarios for the next twenty-five years, and his view on the first was unambiguous:
Scenario 1 — Conservative: Continue as distributor and mid-sized manufacturer. 8–10% annual growth. ₹200–400 crore by 2040. “That’s not a real achievement. No way. For 25 years, only 100% growth? Nope.”
Scenario 2 — Strategic Expansion: Invest in manufacturing, automation technology, and R&D. 12–18% growth. ₹800–1,500 crore by 2050. This is the path he advocates — with a target of ₹1,000 crore as the formal milestone, and ₹2,000 crore as the ultimate 2050 ambition.
Scenario 3 — Best Case: Not discussed in detail. “Just a scenario.” The implication: stretch targets are useful orientations, not promises.
His revenue roadmap was precise: from ₹100 crore in 2026, grow to ₹200 crore in Phase 1, ₹500 crore in Phase 2, and ₹1,000+ crore in Phase 3 — with incremental annual targets of ₹30–40 crore, described as “a realistic target going through so many motions.”
The Mission Statement — Manufacturing, or Stagnation
If there was one sentence that crystallised the entire presentation — and the next generation’s mandate — it was delivered quietly, almost conversationally, near the close:
“Distribution builds revenue. Manufacturing builds profit. Technology builds valuation.”
This is not a strategic preference. It is a structural analysis. And it carries an implicit warning: a company that remains purely a distributor can grow its revenue indefinitely and still not build the kind of institutional value — the brand equity, the gross margins, the proprietary leverage — that sustains an organisation across generations.
Koundinya went further. He identified the specific threats that make this transition not optional but existential:
Gujarat manufacturers are already producing basic balances and expanding. “What makes us think they won’t start manufacturing lab balances and capture the market? They will — in 25 years — unless we establish our brand first.”
Direct principal offices: “Google and Apple are opening offices in India. What makes us think international lab equipment companies won’t do the same in 5 to 10 years? Once they have direct sales operations, there is no need for a channel partner.”
AI and automation disruption: Lab automation is growing at 5–15% annually. Customers are beginning to expect data-driven instruments as standard. “If we don’t adapt, someone else who knows technology will take over from us. As simple as that.”
The Swiggy-Ola analogy he deployed was sharp and effective: “Did any Swiggy representative come and train you? It became a necessity and you adapted. Technology is the same. People need to adapt — or they stagnate.”
The Manufacturing Reality — Honest About the Difficulty
What distinguished Koundinya’s presentation from a purely aspirational strategy document was his willingness to describe exactly how hard the manufacturing ambition is to execute.
He and Murali have been to China exploring solutions for lab balances. Eight months passed without progress. The critical insight they returned with: load cells — the heart of any precision balance — are manufactured nowhere in the world except Taiwan. Not China. Not India. Taiwan. And Taiwanese manufacturers primarily speak Mandarin or Taiwanese, not English.
“These are the bottlenecks,” he said, without drama. “There is no one in India that manufactures a load cell. No one in China either. Only Taiwan.”
A software solution provider has been identified. A hardware design capability exists. The load cell — the one component that cannot be substituted — requires a trip to Taiwan, a negotiation, a relationship. “We need to plan and go there.”
He described Smart Labtech’s manufacturing target not as competing with Sartorius or Mettler — “that would be stupidness” — but as capturing the mid-market: the 3, 4, and 5-decimal balance segment where pharma customers need reliability and compliance, but where imported German or Swiss instruments at premium prices are not the only acceptable answer.
“Our market, our focus is going to be on the margin and the drag gap,” he said, with the clarity of someone who has thought through the competitive positioning carefully. “This is a crystal clear concept.”
The Call to Action — Collective, Not Delegated
Koundinya closed as he had opened: directly.
“It’s not just him setting a target or me giving a presentation. It’s a collective effort. People should be proactive. People should define their own processes and start acting on their initiatives.”
He acknowledged the generation gap explicitly — that the previous generation of employees would “really like to explore, go meet customers, make connections,” while the current generation sometimes prefers comfort. He was not dismissive of either. But he was clear about which tendency serves a company with a ₹1,000 crore ambition.
The next five to seven years, he said, are the deciding window. If manufacturing is established, if the brand is built, if technology is embedded: “We have an exponential and bright future ahead and we can celebrate 50 years without second thoughts.”
If not — “if we remain the same, being a distributor, a supplier and a mid-size manufacturing company” — Smart Labtech will remain exactly that. Not collapsed. Not failed. But not transformed either.
For a company that has been built by a man who started in Balanagar in 2001 with a conviction that Indian science deserved better, that outcome would be the quietest kind of failure — not a fall, but a plateau.
His son, clearly, has no intention of letting that happen.
